Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2522-2528

  Johnston, Eileen ^a   Crawford, Jeffrey ^a   Blackwell, Susan ^a   Bjurstrom, Toni ^a   Lockbaum, Pamela ^a   Roskos, Lorin ^a   Yang, Bing Bing ^a   Gardner, Sheila ^a   Miller Messana, Mary Ann ^a   Shoemaker, Debra ^a   Garst, Jennifer ^a   Schwab, Gisela ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SD 01; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033946028     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2522     Document Type: Article

References (12)

1. Welte K, Gabrilove J, Bronchud MH, et al: Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88:1907-1929, 1996
2. Delgado C, Francis GE, Fisher D: The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9:249-304, 1992
3. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
4. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
5. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
6. Zinzani PL, Pavone E, Storti S, et al: Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974-3979, 1997
7. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo controlled phase III study of lenograstim (glycosylated recombinant human granulocyte-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration. Leuk Lymphoma 25:289-300, 1997
8. Frei E 3rd, Elias A, Wheeler C, et al: The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 4:2027-2037, 1998
9. Cheung E, Cozenza M, Lopez O, et al: Modeling of r-metHuG-CSF-SD/01 mediated granulopoiesis in normal animals, with mathematical extrapolation to neutropenia settings. Blood 92:379a, 1998 (abstr 1563)
10. Roskos LK, Yank B, Schwab G, et al: A cytokinetic model of r-metHUG-CSF-SD/01 mediated granulopoiesis and "self-regulation" of SD-01, elimination in non-small cell lung cancer patents. Blood 92:507a, 1998 (abstr 2085)
11. Farese AM, Roskos L, Cheung E, et al: A single administration of r-metHuG-CSF-SD-01 significantly improves neutrophil recovery following autologous bone marrow transplantation. Blood 92:112a, 1998 (abstr 455)
12. Schwab G, Roskos L, Molineux G, et al: A phase 1 study of sustained-duration filgrastim in normal volunteers. Exp Hematol 26: 709, 1998 (abstr 95)